Wednesday, June 24, 2020
7:00 pm (ET)
SERIES TITLE
Advanced Perspectives in MS: A Virtual Journal Club Series for the Multiple Sclerosis Clinician
ARTICLE TITLE
The COVID-19 Pandemic and the Use of MS Disease Modifying Therapies
TARGET AUDIENCE
This activity has been designed to meet the educational needs of physicians, PAs, nursing professionals, and other members of the healthcare team involved in the management of patients with MS.
LEARNING OBJECTIVES
Upon completing this activity, participants should be better able to:
Identify the latest research and clinical information available describing use of disease modifying therapies in patients with MS during the COVID-19 pandemic.
FACULTY
John F. Kramer, PA-C
STMP Neurology
Nashville, TN
Bryan D. Walker, MHS, PA-C, MSCS
Duke University Medical Center
Durham, NC
COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by educational grants from Celgene Corporation, EMD Serono, Genentech, and Mallinckrodt Pharmaceuticals.
ACCREDITATION STATEMENT AND CREDIT DESIGNATION
In support of improving patient care, the Consortium of Multiple Sclerosis Centers (CMSC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The CMSC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.
PHYSICIANS
The Consortium of Multiple Sclerosis Centers designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PAs
The Consortium of Multiple Sclerosis Centers designates this live activity for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
NURSES
The Consortium of Multiple Sclerosis Centers designates this live activity for 1.0 contact hours of continuing education (1.0 in the area of pharmacology) for nurses.
PHARMACISTS
This knowledge-based activity (UAN # JA4008165-0000-20-029-L01-P) qualifies for 1.0 contact hour (0.1 CEUs) of continuing pharmacy education credit.
All other healthcare professionals completing this activity will be issued a certificate of participation.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
In accordance with the ACCME Standards for Commercial Support, CMSC requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. CMSC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC seeks to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC is committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
FACULTY DISCLOSURES
The program faculty reported the following relevant financial relationships that they have with commercial interests:
John F. Kramer, PA-C (Planner) has disclosed the following relevant financial relationships: Consulting Fees: Biogen, EMD Serono, and Novartis Pharmaceuticals; Speakers Bureau: Alexion, Biogen, EMD Serono, and Genentech.
Bryan D. Walker, MHS, PA-C, MSCS (Planner) has disclosed the following relevant financial relationships: Consulting Fees: Biogen, EMD Serono, Novartis, and Sanofi-Genzyme; Speakers Bureau: Biogen.
STAFF DISCLOSURES
The planners, reviewers, editors, staff, or other members at CMSC who are in a position to control content have declared that they have no relevant financial relationships.
DISCLOSURE OF UNLABELED USE
CMSC requires faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
DISCLAIMER
CMSC presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC and the commercial supporters assume no liability for the information herein.
COPYRIGHT
Multiple Sclerosis and Related Disorders 39 (2020) 102073
The COVID-19 pandemic and the use of MS disease-modifying therapies
Gavin Giovannonia,*, Chris Hawkesa, Jeannette Lechner-Scottb, Michael Levyc, Emmanuelle Waubantd, Julian Golda,e
a Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK
b School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia
c NMO Clinic and Research Laboratory, Division of Neuroimmunology & Neuroinfectious Disease, Massachusetts General Hospital, Boston, USA
d Department of Neurology, UC San Francisco, San Francisco, California, USA
e The Albion Centre, Prince of Wales Hospital, Sydney, New South Wales, Australia
Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre – including this research content – immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT
To successfully complete this live activity, the participant must review the accreditation information, including learning objectives and faculty disclosures, view the webinar, and complete the evaluation.
Participants will receive a detailed email to complete the evaluation and claim their credit the day after the live webinar.
TECHNICAL REQUIREMENTS
This activity is best viewed using the most up to date version of Google Chrome, FireFox, Safari, or Microsoft Edge.
There is no fee to participate in this activity.
PRIVACY POLICY
To view the CMSC Privacy Policy, visit our website at https://www.mscare.org/privacy.aspx
CONTACT INFORMATION
If you have any questions about this activity, please contact the CMSC at [email protected] or 201-487-1050, ext. 102.